Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Goat / IgG|
|Immunogen||Synthetic peptide sequence (HLKTQAEQLHNH) corresponding to the C-terminus amino acids of TAZ|
|Purification||Antigen affinity chromatography|
|Storage buffer||TBS, pH 7.3, with 0.5% BSA|
|Contains||0.02% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||0.3-1.0 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody is predicted to react with canine, mouse and rat based on sequence homology.
This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy , hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction . Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
BTHS; cardiomyopathy, dilated 3A (X-linked); CMD3A; EFE; EFE2; FLJ27390; G4.5; HGNC:11577; LVNCX; OTTHUMP00000061673; protein G4.5; tafazzin; tafazzin (cardiomyopathy, dilated 3A (X-linked) endocardial fibroelastosis 2 Barth syndrome); TAZ; Taz1; XAP-2; XX-FW83563B9.3
BTHS; CMD3A; EFE; EFE2; G4.5; LVNCX; TAZ; Taz1